Equities

Tibet Weixinkang Medicine Co Ltd

603676:SHH

Tibet Weixinkang Medicine Co Ltd

Actions
Health CarePharmaceuticals and Biotechnology
  • Price (CNY)7.48
  • Today's Change-0.04 / -0.53%
  • Shares traded1.23m
  • 1 Year change-29.57%
  • Beta--
Data delayed at least 15 minutes, as of Sep 20 2024.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Profile data is unavailable for this security.

About the company

Tibet Weixinkang Medicine Co., Ltd. is a China-based company principally engaged in the research and development, production and sales of chemical medicines and related active pharmaceutical ingredients (APIs). The Company's main products include injection of complex vitamins, injection of potassium aspartate magnesium, sucrose iron injection and potassium aspartate injection. The Company is also engaged in the production and sales of liver protection drugs and antibiotics products. The Company mainly distributes its products in the domestic market.

  • Revenue in CNY (TTM)1.21bn
  • Net income in CNY243.48m
  • Incorporated2006
  • Employees701.00
  • Location
    Tibet Weixinkang Medicine Co Ltd3F, Block 4, Industry Center, No. 5Yuanqu South Road, Zone B, Lasa EconomicLASA 850000ChinaCHN
  • Phone+86 8 916601760
  • Fax+86 8 916601760
  • Websitehttp://www.wxkpharma.com/
More ▼

Peer analysis

Key Information
CompanyRevenue (TTM)Net income (TTM)Market capEmployeesPrice/earnings (TTM)Price/book value (MRQ)Price/cash flow (TTM)Price/sales (TTM)EPS (excl. extraordinary items, TTM)EPS (incl. extraordinary items, TTM)Revenue per share (TTM)Book value per share (MRQ)Asset turnover (TTM)Inventory turnover (TTM)Receivables turnover (TTM)Revenues per employee (TTM)Return on avg assets (TTM)Return on avg assets (5 yr avg)Return on investment (TTM)Return on investment (5 yr avg)Gross margin (TTM)Gross margin
(5 yr avg)
Net profit margin (TTM)Net Profit margin
(5 yr avg)
Quick ratio (MRQ)Interest coverage (TTM)Total debt to capital (MRQ)Payout ratio
(5 yr avg)
Revenue
(YOY change %)
Revenue
(5 yr growth rate)
Net income
(YOY change %)
Net income
(5 yr growth rate)
Capital expenditure
(5 yr growth rate)
Dividend
(5 yr growth rate)
Tibet Weixinkang Medicine Co Ltd1.21bn243.48m3.27bn701.0013.442.33--2.710.55950.55952.773.220.664917.005.181,721,074.0013.428.2017.7411.1351.4350.2020.1811.532.75--0.007359.11-5.4312.1320.9423.85-5.6138.96
Beijing Konruns Pharmaceutical Co Ltd874.20m136.76m3.33bn447.0024.051.06--3.810.86430.86435.5119.630.22931.823.011,955,707.004.505.435.316.2488.3089.9319.6220.762.93--0.043521.536.15-2.0848.24-10.6343.05-9.71
ChengDu Sheng Nuo Biotec Co Ltd460.12m71.98m3.35bn1.13k46.473.80--7.280.64390.64394.117.880.33810.88084.89407,912.205.287.476.869.4460.5070.5215.6315.820.935413.130.312421.839.939.379.0818.6954.71--
Zhejiang Starry Pharmaceutical Co Ltd2.44bn31.85m3.36bn1.85k87.771.24--1.370.08730.08736.756.160.42041.895.341,323,881.000.55883.301.135.9722.3832.351.338.210.64911.340.520153.083.0419.78158.32-13.9410.39--
Chengdu Olymvax Biopharmaceuticals Inc489.20m-38.94m3.41bn471.00--3.88--6.98-0.096-0.0961.212.170.3110.36770.99841,038,635.00-2.913.17-4.184.6893.5993.00-9.357.441.65-5.250.2869.82-9.3845.40-33.94--56.47--
Data as of Sep 20 2024. Currency figures normalised to Tibet Weixinkang Medicine Co Ltd's reporting currency: Chinese Yuan Renminbi CNY

Institutional shareholders

1.38%Per cent of shares held by top holders
HolderShares% Held
Essence Fund Co., Ltd.as of 31 Dec 20232.75m0.64%
Great Wall Fund Management Co., Ltd.as of 31 Dec 20231.20m0.28%
Rongtong Fund Management Co., Ltd.as of 31 Dec 2023500.00k0.12%
Nanhua Fund Management Co. Ltd.as of 31 Dec 2023386.60k0.09%
Dongxing Asset Management Co. Ltd.as of 31 Dec 2023345.00k0.08%
Hongde Fund Management Co., Ltd.as of 31 Dec 2023275.40k0.06%
Xinyuan Asset Management Co., Ltd.as of 31 Dec 2023192.80k0.05%
GF Fund Management Co., Ltd.as of 31 Dec 2023116.00k0.03%
Acadian Asset Management LLCas of 30 Jun 202472.30k0.02%
Tebon Fund Management Co. Ltd.as of 31 Dec 202372.30k0.02%
More ▼
Data from 31 Dec 2023 - 30 Jun 2024Source: FactSet Research Systems Inc.
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.